In an effort to increase patient access to affordable drugs, California recently created Cal Rx, a state-sponsored generic prescription drug label. Precision's Jason Shafrin weighs in on the potential impact the law ultimately will have.
Research suggests that new cancer treatments have played an especially important role in reducing mortality rates in certain cancers over the past several decades. Disruption to the industry from the COVID-19 pandemic threatens this progress.
Congratulations to PRECISIONadvisors and PRECISIONheor for presenting more than a dozen posters and panels at Virtual ISPOR Europe 2020, 16 - 19 November, 2020.
Multiple factors have contributed to recent reductions in cancer mortality, including declines in smoking rates, treatment advances and better screening. But a key question remains: how much have recent developments in oncology treatments contributed to the decline of cancer mortality in the USA?
Congratulations to Precision Medicine Group Co-Founder and CEO Mark Clein on his moderated Point: Counterpoint panel at this year’s HLTH Conference.
Moderated by Precision's Ross Maclean, our distinguished panel of experts provide key insights on why social determinants of health (SDOH) are critical factors to inform today's treatment planning, care delivery, health policy, health outcomes and value.
Precision's Jason Shafrin identifies three key trends to consider when assessing the value of new innovations for 2021.
In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers.
The COVID-19 pandemic has put the inequality in health outcomes in the United States center stage. What can the healthcare industry do to begin to address disparities in health outcomes?
Expanding traditional value frameworks to include inequality and factors that contribute to this is the first step to addressing disparities in health outcomes.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
